Medpace Holdings, Inc. (NASDAQ:MEDP) Shares Sold by BI Asset Management Fondsmaeglerselskab A S

BI Asset Management Fondsmaeglerselskab A S lessened its position in Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 12.5% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 15,893 shares of the company's stock after selling 2,269 shares during the quarter. BI Asset Management Fondsmaeglerselskab A S owned approximately 0.05% of Medpace worth $5,280,000 at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. R Squared Ltd purchased a new stake in Medpace during the 4th quarter worth about $30,000. SBI Securities Co. Ltd. purchased a new position in Medpace in the fourth quarter worth approximately $31,000. Jones Financial Companies Lllp grew its holdings in Medpace by 2,750.0% during the 4th quarter. Jones Financial Companies Lllp now owns 114 shares of the company's stock worth $38,000 after acquiring an additional 110 shares in the last quarter. Lindbrook Capital LLC increased its position in shares of Medpace by 27.6% in the 4th quarter. Lindbrook Capital LLC now owns 134 shares of the company's stock valued at $45,000 after purchasing an additional 29 shares during the last quarter. Finally, Assetmark Inc. increased its position in shares of Medpace by 20.1% in the 4th quarter. Assetmark Inc. now owns 173 shares of the company's stock valued at $57,000 after purchasing an additional 29 shares during the last quarter. Institutional investors and hedge funds own 77.98% of the company's stock.

Medpace Stock Down 1.4 %

Shares of MEDP traded down $4.33 during trading hours on Friday, reaching $298.55. 399,606 shares of the company traded hands, compared to its average volume of 339,158. The stock has a fifty day simple moving average of $313.79 and a 200 day simple moving average of $331.76. Medpace Holdings, Inc. has a fifty-two week low of $250.05 and a fifty-two week high of $459.77. The stock has a market capitalization of $9.02 billion, a PE ratio of 23.64, a price-to-earnings-growth ratio of 3.81 and a beta of 1.46.

Medpace (NASDAQ:MEDP - Get Free Report) last announced its quarterly earnings data on Monday, April 21st. The company reported $3.67 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.06 by $0.61. The business had revenue of $558.57 million for the quarter, compared to the consensus estimate of $528.38 million. Medpace had a net margin of 19.17% and a return on equity of 51.48%. During the same quarter in the prior year, the firm posted $3.20 earnings per share. Research analysts predict that Medpace Holdings, Inc. will post 12.29 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on the company. Mizuho decreased their target price on Medpace from $400.00 to $355.00 and set an "outperform" rating for the company in a research note on Wednesday, April 9th. Robert W. Baird reduced their price objective on shares of Medpace from $340.00 to $313.00 and set a "neutral" rating for the company in a research report on Wednesday. TD Cowen downgraded shares of Medpace from a "buy" rating to a "hold" rating and dropped their target price for the company from $370.00 to $328.00 in a research report on Monday, April 14th. William Blair reiterated a "market perform" rating on shares of Medpace in a research note on Tuesday. Finally, Leerink Partnrs upgraded shares of Medpace to a "hold" rating in a research note on Monday, March 24th. Eleven research analysts have rated the stock with a hold rating and three have given a buy rating to the company's stock. According to data from MarketBeat, Medpace currently has an average rating of "Hold" and an average target price of $349.30.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.